MARKET

BVXV

BVXV

BiondVax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.630
+0.010
+0.28%
After Hours: 3.540 -0.09 -2.48% 19:57 03/08 EST
OPEN
3.600
PREV CLOSE
3.620
HIGH
3.760
LOW
3.340
VOLUME
113.83K
TURNOVER
--
52 WEEK HIGH
62.00
52 WEEK LOW
2.350
MARKET CAP
51.99M
P/E (TTM)
-2.9884
1D
5D
1M
3M
1Y
5Y
Influenza Vaccines Market Size Estimated to Flourish at USD 7.5 billion by 2027
Market Insight Reports · 02/25 06:10
Influenza Vaccines Market Report 2021 Recent Development and Trends, Expected Growth and its Factors, CAGR, Industry Size, Business Prospects and Forecast 2026 | Says Kenneth Research
Feb 24, 2021 (AmericaNewsHour) -- Influenza Vaccine Market is expected to reach more than US$ 1 Billion across the 5 major markets (5MM) of the France,...
AmericaNewsHour · 02/24 12:22
United States Influenza Vaccine Market Report 2021 Industry Trends, Share and Size, Complete Data Analysis across the Region and Globe, Opportunities and Growth Forecast 2026 | Says Kenneth Research
Feb 24, 2021 (AmericaNewsHour) -- United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022. Market...
AmericaNewsHour · 02/24 12:22
United States Influenza Vaccines Market by Size, Growth, Opportunity and Forecast to 2027
Market Insight Reports · 02/24 05:54
Influenza Vaccine Market Size 2021-2026 By Prominent Players, Investment Opportunities, Regional Segmentation, Share Estimation, Revenue Expectation and Business Prospect, Says Industry Research Biz
The Express Wire · 02/23 07:54
Global Influenza Vaccines Market Size 2021 | Industry Statistics, Emerging Technologies, Business Challenges, Covid-19 Outbreak, Segmentation, Explosive Factors of Revenue Expansion and Strategies 2026
Feb 23, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The “Influenza Vaccines Market” Research...
The Express Wire · 02/23 06:01
BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering
, /PRNewswire/ -- (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced that the underwriter ...
PR Newswire - PRF · 02/10 21:30
Influenza Vaccine Market Share, Global Leading Players 2021, Business Overview, Size Estimation, Revenue, Key Drivers by Manufacturers, Upcoming Trends to Forecast 2026
The Express Wire · 02/04 06:13
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BVXV. Analyze the recent business situations of BiondVax through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BVXV stock price target is 81.00 with a high estimate of 81.00 and a low estimate of 81.00.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 249.51K
% Owned: 1.74%
Shares Outstanding: 14.32M
TypeInstitutionsShares
Increased
4
95.99K
New
13
-335.83K
Decreased
2
3.13K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Director
Mark Germain
Chief Executive Officer/President/Director
Ron Babecoff
Chief Financial Officer
Uri Ben-Or
Chief Scientific Officer
Tamar Ben-Yedidia
Other
Yisrael Gewirtz
Director
George Lowell
Director
Yael Margolin
Director
Samuel Moed
Director
Adi Raviv
Director
Jack Rosen
Director
Avner Rotman
Non-Executive Director
Irit Ben-Ami
Independent Director
Ruth Ben Yakar
No Data
About BVXV
BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

Webull offers kinds of Biondvax Pharmaceuticals Ltd - ADR stock information, including NASDAQ:BVXV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BVXV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BVXV stock methods without spending real money on the virtual paper trading platform.